Unjha Formulations Ltd Valuation Shifts Signal Changing Market Perception

Valuation Metrics and Market Context

As of 11 Aug 2026, Unjha Formulations Ltd trades at ₹27.15, marking an 11.96% increase from the previous close of ₹24.25. The stock has approached its 52-week high of ₹29.50, a significant recovery from its 52-week low of ₹17.52. This price appreciation has coincided with a reclassification of its valuation grade from attractive to fair, driven primarily by its current P/E ratio of 25.34 and a P/BV of 3.17.

These figures suggest that while the stock remains reasonably valued, the margin of safety that once attracted value investors has narrowed. The enterprise value to EBITDA ratio stands at 10.52, indicating moderate operational valuation relative to earnings before interest, taxes, depreciation, and amortisation.

Comparative Analysis with Peers

When benchmarked against its pharmaceutical peers, Unjha Formulations occupies a middle ground in valuation terms. For instance, NGL Fine Chem and Hester Bios are classified as very expensive, with P/E ratios of 44.36 and 40.17 respectively, and EV/EBITDA multiples exceeding 26. In contrast, Venus Remedies and TTK Healthcare maintain more attractive valuations, with P/E ratios of 17.49 and 19.63 respectively, and EV/EBITDA multiples around 11.68 and 23.63.

Unjha’s PEG ratio of 0.06 is notably low, suggesting that the stock’s price growth is not yet fully priced in relative to earnings growth expectations. This contrasts with higher PEG ratios among peers such as Jagsonpal Pharma at 2.42 and Fredun Pharma at 0.73, indicating varying growth-to-price dynamics across the sector.

Financial Performance and Returns

Unjha Formulations demonstrates robust financial health, with a return on capital employed (ROCE) of 40.91% and a return on equity (ROE) of 12.50%. These metrics underscore efficient capital utilisation and moderate profitability, which support the current valuation despite the recent upgrade to a fair grade.

From a returns perspective, the stock has outperformed the Sensex over multiple time horizons. Year-to-date, Unjha has delivered an 8.6% return compared to the Sensex’s negative 7.84%. Over one year, the stock gained 13.5% while the benchmark declined by 1.65%. Longer-term returns are even more impressive, with a three-year return of 103.37% versus 19.57% for the Sensex, and a five-year return of 137.53% compared to 43.97% for the index.

Mojo Score and Grade Evolution

Unjha Formulations currently holds a Mojo Score of 31.0, reflecting a cautious market stance. The Mojo Grade has been downgraded from Strong Sell to Sell as of 10 Aug 2026, signalling a slight improvement in sentiment but still indicating a recommendation to avoid accumulation at current levels. The company remains classified as a micro-cap, which often entails higher volatility and risk compared to larger pharmaceutical players.

Valuation Grade Shift: Implications for Investors

The transition from an attractive to a fair valuation grade suggests that Unjha Formulations’ stock price has absorbed much of the positive growth outlook and operational performance. Investors who previously viewed the stock as undervalued may now find the risk-reward balance less compelling, especially given the premium relative to book value and earnings multiples.

However, the company’s strong ROCE and consistent outperformance against the Sensex over medium to long-term periods provide a foundation for potential future gains, should earnings growth accelerate or sector tailwinds strengthen. The low PEG ratio further hints at untapped growth potential, which could justify a re-rating if realised.

Sector and Market Dynamics

The Pharmaceuticals & Biotechnology sector continues to attract investor interest due to its defensive characteristics and growth prospects driven by innovation and increasing healthcare demand. Within this context, Unjha Formulations’ valuation repositioning aligns with broader market trends where investors are becoming more discerning, favouring companies with clear earnings visibility and sustainable competitive advantages.

Investor Takeaway

For investors evaluating Unjha Formulations Ltd, the shift in valuation grade from attractive to fair warrants a more cautious approach. While the company’s fundamentals remain solid, the stock’s premium multiples relative to historical levels and certain peers suggest limited upside from current prices without further earnings acceleration.

Long-term investors may find value in the company’s strong capital efficiency and sector positioning, but should weigh these against the micro-cap risks and recent downgrade in Mojo Grade. Monitoring quarterly earnings and sector developments will be crucial to reassessing the stock’s attractiveness.

In summary, Unjha Formulations Ltd’s valuation adjustment reflects a maturing market view that balances growth potential with price considerations, signalling a nuanced investment case amid evolving sector dynamics.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →